Articles On Imugene (ASX:IMU)

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australian immuno-oncology company, Imugene Limited (ASX: IMU) is developing a pipeline of mimotope-based B-cell immunotherapies against oncology targets that could replace or be used in combination with monoclonal antibodies. The company i...

Imugene is planning two separate Phase 1 clinical trials in 2020 to test a CheckVacc construct and a Vaxinia construct of the CF33 oncolytic virus.

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Biotechnology firm headquartered in Australia, Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology player that develops novel immunotherapies to treat and eradicate cancerous tumours. The company’s unique platform technologies ho...

As per latest update from Imugene Limited (ASX: IMU), the prominent City of Hope researchers have received a Grant of USD 564,173 from the US Department of Defense to study the company’s Oncolytic Virotherapy (OV) CF33 in gastric cancer. Ma...

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced that City of Hope researchers have received a grant from the US Department of Defense Grant related to the use of its technology.

ASX-listed clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) has released an update on the preliminary clinical development plan for the intended exclusive license of the patents encompassing the oncolytic virus technology, CF...

The grant focuses on the area of gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.

Immuno-oncology company Imugene’s (ASX: IMU) oncolytic virotherapy (OV) drug will receive a boost after City of Hope researchers received a US Department of Defense grant to study the drug in gastric cancer sufferers. City of Hope researche...

Botanix Pharmaceuticals’ (ASX:BOT) shares have halved after its anti-acne drug failed its clinical trial. If you read most of the company’s announcement and you’d would have thought the 368 patient trial was a success. Its drug, BTX 1303, w...

A US Department of Defense Grant titled Discovery of Immune Biomarkers That Predict Response to a Novel Chimeric Immuno-Oncolytic Virus Encoding Anti-PD-L1 in Gastric Cancer Peritoneal Carcinomatosis has been awarded to prominent City of Ho...

As the market players are aware, performance of broader Australian markets is expected to be influenced by the health of global economy. Also, performance of global markets can influence the performance of Australian equities. Any sort of e...

Australia-based clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is involved in the development of various new and novel immunotherapies that attempt to stimulate the patient’s immune system to eradicate and treat tumours. Im...

Two separate Phase 1 clinical trials will be conducted in 2020 to test a CheckVacc construct and a Vaxinia construct of the oncolytic virus.

Drug development company Noxopharm (ASX: NOX) is growing more optimistic about the use of its Veyonda treatment on patients with late-stage prostate cancer. NOX provided an interim update on its DARRT-1 clinical trial, where patients are gi...

Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology, which is subject to shareholders’ a...

A pioneer in the operating room and in the laboratory, Dr Fong, The Sangiacomo Family Chair in Surgical Oncology and chair of The City of Hope Dept of Surgery, is a recognised expert in liver and pancreatic cancer.

Australian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is engaged towards the development of several new and novel immunotherapies that work to activate the cancer patients’ immune system to treat and remov...

Inventor Ursula Wiedermann and investigators Tanios Bekaii-Saab and Joshua Tobias presented findings from early study of vaccines for gastric, colon and breast cancers.

“History is bunk!’’ declared industrialist Henry Ford, but unfortunately for the oro-mucosal delivery specialist Suda, distancing itself from its corporate past has not been a simple case of cranking up the Model T and hitting the road. In...

Considered as one of the most interesting corners of the stock market, biotech stocks hold the ability to offer huge profits to investors in a very short span of time. The biotechnology companies are counted amongst those that can grow from...

Australian-headquartered global pharmaceutical leader, SUDA Pharmaceuticals Limited (ASX: SUD) is engaged in the reformulation of existing drugs and provision of medication via the oral mucosa. The company uses its exclusive OroMist® techno...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by “selling” stocks you do not actually own in the hope of...

Drugs intake in the form of pills, capsules, and tablets are not the most efficient ways of taking medicine, because only about 25% of the drug reaches where it should. Several factors including food affect, enzymatic degradation, drug meta...

Imugene Limited (ASX: IMU) is a clinical stage biotechnology company that focuses on the development of immunotherapies that have the potential to enable a patient’s immune system to recognise and destroy cancer cells. The company is focuse...

Imugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focusses on the development of emerging immunotherapies to enhance the efficacy of cancer treatments. The company utilises its unique platform t...

Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of multiple cancers. The company aims to develop novel drugs that work on th...

An Australian-headquartered clinical stage biotechnology company, Imugene Limited (ASX: IMU) seeks to develop different novel immunotherapies to boost the efficacy of cancer treatments. Imugene’s product pipeline covers oncolytic viruses an...

Move over Thomas the Tank Engine – the Oncolytic Express is about to leave the station! The railway analogy is not our own, but the work of Imugene (ASX: IMU) chief Leslie Chong after the company signed a deal to buy an immuno-oncology drug...

An oro-mucosal drug delivery company headquartered in Perth, SUDA Pharmaceuticals Ltd (ASX: SUD) uses its OroMist® technology for the development of low-risk oral sprays. The company reformulates the existing pharmaceuticals into an oral sp...

Queenstown is known as the adventure capital of the world. It attracts over three million people per year to experience the world-class ski runs, zip-line riding, white water rafting, sky diving and is, of course, famous for manufacturing t...

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

An Australian-based biotechnology company, Imugene Limited (ASX: IMU) focuses on the development of cancer immunotherapies targeted at activating the immune system of cancer patients. The company’s exceptional platform technology helps in...

A biotech company headquartered in Australia, Imugene Limited (ASX: IMU) develops new and novel immunotherapies that seek to harness the cancer patients’ immune system against tumors. The company’s unique platform technologies seeks to pote...

Australian immuno-oncology company Imugene (ASX:IMU) has boosted its investigational portfolio through the acquisition of local counterpart Vaxinia with global rights to a new oncolytic virus technology.

A phase-one clinical trial in 30 patients with advanced tumours is expected to start in 2020 across a number of US cancer centres.

A biotechnology company listed on the Australian Stock Exchange (ASX), Imugene Limited (ASX: IMU) develops cancer immunotherapies targeting B-cell peptide vaccines. The immunotherapies developed by the company seek to activate the cancer pa...

Health and medical industry of Australia focuses on the world’s leading technology, advanced research, development and innovation. Over the years, the industry has registered strong growth in terms of both size and reputation. Let us discus...

HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours in gastric, breast, ovarian, lung and pancreatic cancers.

An Australian-headquartered clinical stage immuno-oncology company, Imugene Limited (ASX: IMU) has a robust pipeline of B cell vaccines aimed at treating a variety of cancers. The company’s pipeline includes multiple product candidates that...

The movement of global stock markets is very sensitive to the news which is associated with the trade battle between the US & China, and other macro-economic variables. Not so long ago, it can be said that the global market players were...

Imugene Limited (ASX: IMU) is a clinical-stage immuno-oncology company headquartered in Australia that is engaged in developing a range of immunotherapies used to treat and eradicate tumors. The company’s operations are spread across Americ...

Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.

Imugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field and is developing vaccines to boost and direct the immune system to target and attack cancer cells.